EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Treatment landscape from first‐ to third‐line therapy and quality of life data of patients with pancreatic cancer from the prospective German PARAGON (Platform for Outcome, Quality of Life, and Translational Research on Pancreatic Cancer) registry ( IKF ‐ PARAGON study)

Thorsten O Goetze, Salah-Eddin Al-Batran, Ruediger Liersch, Lars Scheuer, Thomas Goehler, Ulrich Kaiser, Claudio Denzlinger, Stephan Brandl, Daniel Pink, Jens Uhlig, Michael Maasberg, Maria Loose iD und 8 weitere

International Journal of Cancer · 2025

DOI: 10.1002/ijc.70280 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift International Journal of Cancer, 2025. Verfasst von Thorsten O Goetze und 19 weiteren Autor:innen. Beteiligte Einrichtung: University Cancer Center (UCT), Krankenhaus Nordwest, Frankfurt am Main, Germany. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Quality of Life, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Celgene, BMS (formerly Celgene).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pancreatic cancer (PCA) is the third leading cause of cancer‐related death in Europe. Despite recent therapeutic advances, patients experience rapid health deterioration. Based on previous results, the Platform for Outcome, Quality of Life, and Translational Research on Pancreatic Cancer—PARAGON (NCT04119362) was initiated to investigate the whole life cycle of PCA patients. Between November 2019 and October 2021, 469/479 screened patients were enrolled in 46 sites. Demographic, clinical, and quality of life (QoL) data were collected. The treatment landscape was depicted using Sankey diagrams. Median overall survival (mOS) for all patients in first line was 10.6 months (95% confidence interval [CI], 9.2–11.7 months). With mFOLFIRINOX as first‐line treatment, mOS was 11.3 months (95% CI, 8.6–13.5 months), with gemcitabine/nab‐paclitaxel 10.5 months (95% CI, 8.3–12.9 months). The mean Global Health Status for patients that proceeded from first to second line did not substantially deteriorate during first line. Predictive variables for proceeding from first to second‐line therapy were reasons for ending first‐line treatment (patient's wish, toxicity, and progressive disease) and age. In summary, we were able to show in detail patient flows and QoL data throughout all therapy lines, which will help to further understand the major clinical checkpoints of the disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsQuality of LifeAntineoplastic Combined Chemotherapy ProtocolsHumansMaleFemaleAgedMiddle AgedRegistriesGemcitabineDeoxycytidineGermanyProspective StudiesIrinotecanPaclitaxelOxaliplatinFluorouracilTranslational Research, BiomedicalAged, 80 and overLeucovorinAdultAlbuminsTreatment Outcome

Stichwörter der Autor:innen

pancreatic cancerquality of lifetreatment sequence

Substanzen

GemcitabineDeoxycytidineIrinotecanPaclitaxelOxaliplatinFluorouracilfolfirinox130-nm albumin-bound paclitaxelLeucovorinAlbumins

Autor:innen und Institutionen

  • University Cancer Center (UCT), Krankenhaus Nordwest, Frankfurt am Main, Germany.
  • University Cancer Center (UCT), Goethe University Frankfurt, Frankfurt am Main, Germany.
  • The Frankfurt Institute of Clinical Cancer Research, IKF, Frankfurt am Main, Germany.
  • GEHO, Practice for Hematology and Medical Oncology, Münster, Germany.
  • Onkologische Schwerpunktpraxis Speyer, Speyer, Germany.
  • Onkozentrum Dresden/Freiberg/Meißen, Dresden, Germany.

ORCID-Profile: Maria Loose, Christine Koch

Förderung

  • Celgene
  • BMS (formerly Celgene)

Zitieren

APA

Goetze, T. O., Al-Batran, S. E., Liersch, R., Scheuer, L., Goehler, T., Kaiser, U., Denzlinger, C., Brandl, S., Pink, D., Uhlig, J., Maasberg, M., Loose, M., Schaaf, M., Sookthai, D., Zäpf, B., Pauligk, C., Habibzade, T., Hofheinz, R. D., Koch, C., & AIO Study Group (2025). Treatment landscape from first‐ to third‐line therapy and quality of life data of patients with pancreatic cancer from the prospective German PARAGON (Platform for Outcome, Quality of Life, and Translational Research on Pancreatic Cancer) registry ( IKF ‐ PARAGON study). International Journal of Cancer. https://doi.org/10.1002/ijc.70280

Vancouver

Goetze TO, Al-Batran SE, Liersch R, Scheuer L, Goehler T, Kaiser U, et al. Treatment landscape from first‐ to third‐line therapy and quality of life data of patients with pancreatic cancer from the prospective German PARAGON (Platform for Outcome, Quality of Life, and Translational Research on Pancreatic Cancer) registry ( IKF ‐ PARAGON study). International Journal of Cancer. 2025. doi:10.1002/ijc.70280

BibTeX
@article{Goetze2025,
  author = {Goetze, Thorsten O and Al-Batran, Salah-Eddin and Liersch, Ruediger and Scheuer, Lars and Goehler, Thomas and Kaiser, Ulrich and Denzlinger, Claudio and Brandl, Stephan and Pink, Daniel and Uhlig, Jens and Maasberg, Michael and Loose, Maria and Schaaf, Marina and Sookthai, Disorn and Zäpf, Bianca and Pauligk, Claudia and Habibzade, Timursah and Hofheinz, Ralf-Dieter and Koch, Christine and AIO Study Group, AIO Study Group},
  title = {Treatment landscape from first‐ to third‐line therapy and quality of life data of patients with pancreatic cancer from the prospective German PARAGON (Platform for Outcome, Quality of Life, and Translational Research on Pancreatic Cancer) registry ( IKF ‐ PARAGON study)},
  journal = {International Journal of Cancer},
  year = {2025},
  doi = {10.1002/ijc.70280}
}
Kostenlos starten →